TerminatedPhase 2NCT03930771

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

Studying Pituitary adenoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Weill Medical College of Cornell University
Principal Investigator
Rajiv Magge, MD, M.D
Weill Medical College of Cornell University
Intervention
Capecitabine(drug)
Enrollment
1 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03930771 on ClinicalTrials.gov

Other trials for Pituitary adenoma

Additional recruiting or active studies for the same condition.

See all trials for Pituitary adenoma →

← Back to all trials